


Eduardo A. Guzman
916 posts

@eduguzman
Eduardo A. Guzman MD. Surgical Oncology.




TWO DAYS after receiving the application, FDA greenlit the new pancreatic cancer drug daraxonrasib for expanded access. This drug has also been granted a national priority voucher, which means a full application could be reviewed in a matter of weeks instead of 10-12 months.

A phase III randomized trial of pyloroplasty during minimally invasive esophagectomy was stopped early after demonstrating fewer short-term complications than no pyloroplasty. ovid.com/10.1097/SLA.00…













Among patients at nutritional risk after #Pancreatoduodenectomy, early enteral nutrition in addition to oral intake resulted in a lower overall burden of postoperative complications versus oral nutrition alone. ja.ma/4d0i88w




